Julie Andrews, serving as the Chief Financial Officer of Orthofix Medical Inc. (NASDAQ: OFIX), sold 4,873 shares of the company's common stock on January 16, 2026. The shares were disposed of at a price of $14.38 each, resulting in a total transaction amount of approximately $70,073.
Post-transaction, Andrews' equity stake in Orthofix comprises 58,039 shares. This holding notably includes 45,590 restricted stock units, which are subject to vesting conditions and limitations on transferability.
The share disposal was executed specifically to address tax withholding obligations associated with the vesting of restricted stock units. According to disclosures in the Securities and Exchange Commission (SEC) filing, the sale was compelled by the Compensation and Talent Development Committee of Orthofix's Board of Directors. Andrews exercised no personal discretion in the matter; the transaction was mandated as part of fulfilling the tax requirements.
In a separate announcement, Orthofix Medical Inc. released its financial results for the third quarter of 2025, which depicted a complex financial landscape. The company reported earnings per share (EPS) of -$0.57, falling short of analyst expectations that had forecasted an EPS of -$0.33. This miss reflects a negative surprise of roughly 72.73%, raising some concerns among investors and stakeholders.
Contrasting the earnings disappointment, Orthofix beat revenue projections by recording sales of $203.4 million, which exceeded the expected $200.26 million. This revenue outperformance adds nuance to the company's financial status, underscoring both challenges and strengths in recent operations.
The juxtaposition of these figures highlights the complexity of Orthofix's current financial performance, with the earnings shortfall shadowing the favorable revenue results. These mixed results will continue to be an important aspect of the company’s evolving financial narrative.